T 2440/13 (Rituximab/BIOGEN) of 20.09.2016
- European Case Law Identifier
- ECLI:EP:BA:2016:T244013.20160920
- Date of decision
- 20 September 2016
- Case number
- T 2440/13
- Petition for review of
- -
- Application number
- 05022104.3
- IPC class
- A61K 39/395
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Chimeric anti-CD20 antibody, rituxan, for use in the treatment of chronic lymphocytic leukemia
- Applicant name
- Biogen Inc.
- Opponent name
- Althausen, Sonja
Teva Pharmaceutical Industries Ltd.
Gedeon Richter Pharma GmbH
Rumpold, Tino
Royle, Matthew Charles James
Sandoz AG
Merck & Co. - Board
- 3.3.04
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 123(2)European Patent Convention R 115(2)Rules of procedure of the Boards of Appeal Art 12(4)Rules of procedure of the Boards of Appeal Art 15(3)
- Keywords
- Main request, auxiliary requests 1 to 3: amendments - allowable (no)
- Catchword
- -
- Citing cases
- -
Order
For these reasons it is decided that:
The appeal is dismissed.